Proficient in current pharmaceutical regulations, standards and best practices. Analytical and detail-oriented professional focused on making sure products meet all relevant domestic and international regulatory requirements. Methodical and objective with good judgment and sound critical thinking and problem-solving abilities.
PUBLICATIONS
• Affordability, availability, and tolerability of anti-seizure medications are better predictors of adherence than beliefs: Changing paradigms from a low resource setting.
Seizure: European Journal of Epilepsy 83(2020)208-215.
• Alteration in renal function following loop diuretics in patients with acute decompensated heart failure.
Asian Journal of Pharmaceutical and Clinical Research Vol 12, Issue 12, 2019,1-3.
PAPERS PRESENTED
• ‘Alteration in renal function following loop diuretics in patients with acute decompensated heart failure’, 4th International Conference on Clinical Pharmacy, Manipal College of Pharmaceutical Sciences, India. Jan 2019
• Poster presentation on Chemotherapy Awareness, PSG Super Specialty Hospitals, India. Feb 2018
Northeastern University, Boston, MA 09/2021 - 12/2023
• Informed Consent form: Designed an informed consent form as per 21 CFR part 50(b).
• Case studies: Falsified Medicines and Electronic Cigarettes in the EU: Political Economy and Product Regulation.
• Drafted: Pre-NDA Meeting Request, FDA Form 2252, FDA Form 356h, Safety Labeling Changes.
• Framed a new protocol to an open IND and submitted an annual report to an open IND.
• Biopharmaceutical Quality Management System (QMS) Requirements: Submission Plan and Quality Manual.
• Prepared an integrated summary of safety (ISS) and integrated summary of effectiveness (ISE) for a new drug.
• Group Projects: Team Leader:
i. Prepared Table of Contents (TOC) for a Clinical Study Report (CSR) in eCTD format.
ii. Prepared an SOP in eCTD format.
iii. Prepared an IND in eCTD format.